IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v3y2019i4d10.1007_s41669-019-0137-0.html
   My bibliography  Save this article

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta

Author

Listed:
  • Ilke Akpinar

    (University of Alberta)

  • Arto Ohinmaa

    (University of Alberta)

  • Lars Thording

    (Innovative Health)

  • Dat T. Tran

    (University of Alberta)

  • Richard N. Fedorak

    (University of Alberta)

  • Lawrence Richer

    (University of Alberta)

  • Philip Jacobs

    (University of Alberta)

Abstract

Objective Our objective was to describe the costs of industry-sponsored clinical trials for medical devices in Northern Alberta, Canada. Methods We used centralized data to identify all industry-sponsored medical device clinical trials initiated in Northern Alberta from 2012 to 2016. For each arm of each trial, we calculated the price of devices provided by the sponsor and the cost of clinical and administrative services that were incurred to clinically operationalize the treatment. Results Our sample consisted of 18 device trials initiated between January 2012 and January 2016. The overall cost (Canadian dollars [$Can], year 2018 values) per enrolee was $Can18,243 for the experimental arm and $Can13,827 for the control arm. Devices were the highest cost component, at $Can13,446 per enrollee in the experimental arm. Clinical costs in the control arms were higher on average ($Can7202 vs. 2504) than those in the experimental arms. Conclusion Data from industry-sponsored clinical trials can provide important information on the full costs of device-related interventions. As device costs rise, and as policy makers require more evidence on device-related treatments, the cost of medical device-driven interventions should be documented along with their effectiveness.

Suggested Citation

  • Ilke Akpinar & Arto Ohinmaa & Lars Thording & Dat T. Tran & Richard N. Fedorak & Lawrence Richer & Philip Jacobs, 2019. "The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta," PharmacoEconomics - Open, Springer, vol. 3(4), pages 591-597, December.
    • Handle: RePEc:spr:pharmo:v:3:y:2019:i:4:d:10.1007_s41669-019-0137-0
    DOI: 10.1007/s41669-019-0137-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-019-0137-0
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1007/s41669-019-0137-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Daniel Gladwell & Thea Henry & Mark Cook & Ron Akehurst, 2014. "Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK," Applied Health Economics and Health Policy, Springer, vol. 12(6), pages 611-622, December.
    2. Ilke Akpinar & Philip Jacobs & Dat T. Tran, 2017. "Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”," PharmacoEconomics - Open, Springer, vol. 1(1), pages 71-71, March.
    3. Ilke Akpinar & Philip Jacobs & Tien Dat Tran, 2017. "Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review," PharmacoEconomics - Open, Springer, vol. 1(1), pages 65-68, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:3:y:2019:i:4:d:10.1007_s41669-019-0137-0. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.